

UGANDA – PNEUMOCOCCAL VACCINE SUPPORT
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uganda			
2. Grant Number: 15-UGA-12b-X			
3. Date of Decision Letter: 15 September 2014			
4. Date of the Partnership Framework Agreement: 28 June 2013			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID			
8. Programme Duration¹: 2013 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2013-2014	2015	Total ²
Programme Budget (US\$)	US\$34,999,755 ³	US\$24,653,500	US\$59,653,255
10. Vaccine Introduction Grant: Not applicable.			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with GAVI funds in each year	2013-2014	2015	
Number of Pneumococcal vaccines doses		4,581,200	
Number of AD syringes		4,871,700	
Number of safety boxes		53,600	
Annual Amounts (US\$)	US\$34,999,755 ⁵	US\$24,653,500	
12. Procurement agency: UNICEF.			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable.									
<p>14. Co-financing obligations: Reference code: 15-UGA-12b-X-C According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2015</td> </tr> <tr> <td>Number of vaccine doses</td> <td>280,400</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$944,302</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$972,500</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	280,400	Value of vaccine doses (US\$)	US\$944,302	Total Co-Financing Payments (US\$) (including freight)	US\$972,500
Type of supplies to be purchased with Country funds in each year	2015								
Number of vaccine doses	280,400								
Value of vaccine doses (US\$)	US\$944,302								
Total Co-Financing Payments (US\$) (including freight)	US\$972,500								
<p>15. Operational support for campaigns: Not applicable.</p> <table border="1"> <tr> <td></td> <td>2015</td> </tr> <tr> <td>Grant amount (US\$)</td> <td></td> </tr> </table>			2015	Grant amount (US\$)					
	2015								
Grant amount (US\$)									
<p>16. Additional documents to be delivered for future disbursements:</p> <table border="1"> <tr> <td>Reports, documents and other deliverables</td> <td>Due dates</td> </tr> <tr> <td>APR or equivalent</td> <td>As agreed with GAVI Secretariat.</td> </tr> </table>		Reports, documents and other deliverables	Due dates	APR or equivalent	As agreed with GAVI Secretariat.				
Reports, documents and other deliverables	Due dates								
APR or equivalent	As agreed with GAVI Secretariat.								
17. Financial Clarifications: Not applicable.									
18. Other conditions: Not applicable.									

Signed by,
On behalf of the GAVI Alliance

Hind Khatib-Othman
 Managing Director, Country Programmes
 15 September 2014